Prescription drugs FDA oversight of directtoconsumer advertising has limitations. PDF Download

Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Prescription drugs FDA oversight of directtoconsumer advertising has limitations. PDF full book. Access full book title Prescription drugs FDA oversight of directtoconsumer advertising has limitations. by . Download full books in PDF and EPUB format.

Prescription drugs FDA oversight of directtoconsumer advertising has limitations.

Author:
Publisher: DIANE Publishing
ISBN: 1428945539
Category :
Languages : en
Pages : 37

Book Description

Prescription drugs FDA oversight of directtoconsumer advertising has limitations.

Author:
Publisher: DIANE Publishing
ISBN: 1428945539
Category :
Languages : en
Pages : 37

Book Description

Prescription Drugs

Author: United States. General Accounting Office
Publisher:
ISBN:
Category : Advertising
Languages : en
Pages :

Book Description

Prescription Drugs

Author:
Publisher:
ISBN:
Category : Advertising
Languages : en
Pages : 33

Book Description

Prescription Drugs: Improvements Needed in FDA’s Oversight of Direct-to-Consumer Advertising

Author:
Publisher: DIANE Publishing
ISBN: 9781422311578
Category :
Languages : en
Pages : 52

Book Description

Prescription Drugs: Trends in FDA's Oversight of Direct-to-Consumer Advertising

Author: Marcia Crosse
Publisher: DIANE Publishing
ISBN: 1437905714
Category : Business & Economics
Languages : en
Pages : 19

Book Description
The FDA is responsible for overseeing direct-to-consumer (DTC) advertising (ad) of prescription drugs, which includes TV, magazines, and the Internet. If FDA identifies a violation of laws or reg¿s. in a DTC ad material, the agency may issue a regulatory letter (RL) asking the drug co. to take specific actions. In 2002, there were delays in FDA¿s issuance of these RL. This testimony discusses trends in FDA¿s oversight of DTC ad and the actions FDA has taken when it identifies violations. This statement discusses the: (1) DTC ad materials FDA reviews; (2) FDA¿s process for issuing RL citing DTC ad materials and the number of RL issued; and (3) the effectiveness of FDA¿s RL at limiting the dissemination of false or misleading DTC ad. Charts and tables.

Prescription Drugs

Author: United States Government Accountability Office
Publisher: Createspace Independent Publishing Platform
ISBN: 9781976365126
Category :
Languages : en
Pages : 52

Book Description
The Food and Drug Administration (FDA) is responsible for overseeing direct-to-consumer (DTC) advertising of prescription drugs. If FDA identifies a violation of laws or regulations in a DTC advertising material, the agency may issue a regulatory letter asking the drug company to take specific actions. GAO was asked to discuss (1) trends in drug company spending on DTC advertising and other activities; (2) what is known about the relationship between DTC advertising and drug spending and utilization; (3) the DTC advertising materials FDA reviews; (4) the number of regulatory letters that cited DTC materials and FDA's process for issuing those letters; and (5) the effectiveness of these letters at limiting the dissemination of violative DTC advertising. GAO reviewed research literature, analyzed FDA's processes, and examined FDA documentation.

Prescription Drugs

Author: Marcia Crosse
Publisher: DIANE Publishing
ISBN: 1437908837
Category : Medical
Languages : en
Pages : 46

Book Description
The FDA regulates the promotion of prescription drugs (PD) to ensure that promotional materials are not false and misleading and that they comply with applicable laws and regulations. FDA prohibits drug co. from promoting PD for off-label uses -- that is, for a condition or patient population for which the PD has not been approved or in a manner that is inconsistent with info. found on the approved PD label. Although doctors may prescribe PD off label, it is not permissible for drug co. to promote PD for off-label uses. FDA may take regulatory actions for violations. This report provides info. about the promotion of PD for off-label uses. It reviewed: how FDA oversees the promotion of off-label uses of PD; and what actions have been taken to address off-label PD.